Shenzhen CNY

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)

54.82 -3.13 (-5.40%)

At close: October 30 at 3:04:45 PM GMT+8

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

GlobeNewswire 1mo ago

002653.SZ
-5.40%
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners

PR Newswire 2mo ago

002653.SZ
-5.40%
Haisco and Nuvectis sign licensing deal for two drugs

Pharmaceutical Technology 4mo ago

002653.SZ
-5.40%
NVCT
Haisco and Nuvectis sign licensing deal for two drugs

Hospital Management 4mo ago

002653.SZ
-5.40%
NVCT
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas

PR Newswire 4mo ago

002653.SZ
-5.40%
LLY
Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)

InvestorsHub 4mo ago

NVCT

002653.SZ
-5.40%
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

Zacks 2mo ago

NVCT

002653.SZ
-5.40%
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

TMX Newsfile 3mo ago

NVCT

002653.SZ
-5.40%
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

GlobeNewswire 4mo ago

NVCT

002653.SZ
-5.40%
AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

Insider Monkey 6mo ago

ABBV

002653.SZ
-5.40%
^GSPC
Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets

Simply Wall St. 4mo ago

LLY

128940.KS

002653.SZ
-5.40%
Eli Lilly Broadens Beyond Obesity Drugs With Vaccine And Genetic Bets

Simply Wall St. 4mo ago

LLY

128940.KS

002653.SZ
-5.40%

Performance Overview

Return	002653.SZ	SSE Composite Index (000001.SS)
YTD	+8.20%	-9.32%
1-Year	+7.83%	-9.73%
3-Year	+128.11%	+19.11%

U.S. markets closed

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)

AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners

Haisco and Nuvectis sign licensing deal for two drugs

Haisco and Nuvectis sign licensing deal for two drugs

Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas

Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets

Eli Lilly Broadens Beyond Obesity Drugs With Vaccine And Genetic Bets